Literature DB >> 8980983

The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment.

G U Meduri1.   

Abstract

The host defence response (HDR) to insults is similar regardless of the tissue involved and consists of an interactive network of simultaneously activated pathways that act in synergy to increase the host's chance of survival. Among this cascade of integrated pathways, three aspects of the HDR, inflammation, coagulation and tissue repair, are analysed separately to explain the histological and physiological changes occurring at the tissue level in unresolving acute respiratory distress syndrome (ARDS). Cellular responses in HDR are regulated by a complex interaction among cytokines, and cytokines have concentration-dependent biological effects. The degree of initial HDR may determine the progression of ARDS. On Day 1 of mechanical ventilation and over time, nonsurvivors of ARDS have significantly higher plasma and bronchoalveolar lavage inflammatory cytokine levels than survivors. In the absence of inhibitory signals, the continued production of HDR mediators prevents effective restoration of lung anatomy and function by sustaining inflammation with tissue injury, intra- and extravascular coagulation and proliferation of mesenchymal cells (fibroproliferation) with deposition of extracellular matrix resulting in fibrosis. Glucocorticoids inhibit the HDR cascade at virtually all levels; their gradual and generalized suppressive influence protects the host from overshooting. In patients with exaggerated HDR, however, cytokine elevation may cause a concentration-dependent resistance to glucocorticoids by reducing glucocorticoid receptor binding affinity. Recent clinical and experimental studies have shown that effective containment of the HDR in unresolving ARDS may be achieved only if glucocorticoid administration is prolonged. A double-blind randomized study is in progress to evaluate the role of prolonged glucocorticoid treatment in unresolving ARDS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980983     DOI: 10.1183/09031936.96.09122650

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  17 in total

1.  Enhanced susceptibility to subcutaneous abscess formation and persistent infection around catheters is associated with sustained interleukin-1beta levels.

Authors:  J J Boelens; S A Zaat; J L Murk; J J Weening; T van Der Poll; J Dankert
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

Review 2.  Understanding ARDS-associated fibroproliferation.

Authors:  Gianfranco Umberto Meduri; Mahmoud A Eltorky
Journal:  Intensive Care Med       Date:  2015-01-08       Impact factor: 17.440

3.  Intersectin-1s: an important regulator of cellular and molecular pathways in lung injury.

Authors:  Dan N Predescu; Cristina Bardita; Rajive Tandon; Sanda A Predescu
Journal:  Pulm Circ       Date:  2013-12-05       Impact factor: 3.017

4.  Effects of methylprednisolone on intracellular bacterial growth.

Authors:  G U Meduri; S Kanangat; M Bronze; D R Patterson; C U Meduri; C Pak; E A Tolley; D R Schaberg
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

5.  Effects of cytokines and endotoxin on the intracellular growth of bacteria.

Authors:  S Kanangat; G U Meduri; E A Tolley; D R Patterson; C U Meduri; C Pak; J P Griffin; M S Bronze; D R Schaberg
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

6.  Interleukin-1 receptor type I gene-deficient mice are less susceptible to Staphylococcus epidermidis biomaterial-associated infection than are wild-type mice.

Authors:  J J Boelens; T van der Poll; S A Zaat; J L Murk; J J Weening; J Dankert
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

7.  Effect of endothelin antagonists, including the novel ET(A) receptor antagonist LBL 031, on endothelin-1 and lipopolysaccharide-induced microvascular leakage in rat airways.

Authors:  D J Hele; M A Birrell; S E Webber; M L Foster; M G Belvisi
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

Review 8.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 9.  Advances in mechanisms of repair and remodelling in acute lung injury.

Authors:  Claudia C Dos Santos
Journal:  Intensive Care Med       Date:  2008-02-09       Impact factor: 17.440

10.  Coagulopathy as a prognostic factor of acute lung injury in children.

Authors:  Young Joo Han; June Dong Park; Jae Wook Choi; Dong In Suh; Young Yull Koh
Journal:  J Korean Med Sci       Date:  2012-12-07       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.